
News|Articles|May 18, 2023
How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer
Author(s)Chris Spivey
Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.
Advertisement
Chris Spivey, editorial director, speaks with Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer. In this interview, True shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry, including changes to the "just-in-time" supply chain, pandemic preparedness, and more.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation
2
CAR T-Cell Trial Pause Signals New Manufacturing Risk Review
3
AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1
4
AAPS PharmSci 360: CMC Strategies, Part 1
5




